JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A8706 BLU9931

Target: FGFR

Summary: FGFR4 inhibitor,potent and irreversible

≥50.9 mg/mL
A3009 Sorafenib
2 Citation

Target: Raf|VEGFR

Summary: Raf kinases and tyrosine kinases inhibitor

≥23.25 mg/mL
A3014 BGJ398
1 Citation

Target: FGFR

Summary: FGFR inhibitor ,potent and selective

insoluble in H2O; insoluble in EtOH; ≥7 mg/mL
A3020 (R)-Crizotinib
2 Citation

Target: c-MET

Summary: C-MET/ALK inhibitor,potent and ATP-competitve

insoluble in H2O; insoluble in EtOH; ≥7.51 mg/mL
A3022 Pazopanib (GW-786034)

Target: CSF-1R|VEGFR|PDGFR|c-Kit|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in EtOH; insoluble in H2O; ≥10.95 mg/mL
A4092 CUDC-101
1 Citation

Target: Histone Deacetylases (HDACs)|EGFR|ErbB

Summary: Multitargeted HDAC inhibitor

≥21.7 mg/mL
A4139 AG-490
3 Citation

Target: EGFR|JAK

Summary: JAK2/EGFR inhibitor

insoluble in H2O; ≥14.7 mg/mL
A4116 Danusertib (PHA-739358)
2 Citation

Target: Aurora Kinases

Summary: Pan-aurora kinase inhibitor

≥23.75 mg/mL
A3145 Afatinib dimaleate

Target: EGFR|HER2

Summary: EGFR inhibitor

≥35.9 mg/mL
A3194 AST 487
1 Citation

Target: RET

Summary: RET kinase inhibitor

≥26.5 mg/mL